Bank Of America Corp Zynerba Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.3 - $0.43 $8 - $11	-27 Reduced 13.5%	173 $0
Q1 2023 May 12, 2023	BUY	$0.4 - $0.67 $19 - $32	48 Added 31.58%	200 $0
Q4 2022 Feb 10, 2023	BUY	$0.5 - $0.72 $25 - $36	51 Added 50.5%	152 $0
Q3 2022 Nov 14, 2022	SELL	$0.87 - $1.36 $261 - $408	-300 Reduced 74.81%	101 $0
Q2 2022 Aug 12, 2022	BUY	$0.86 - $2.06 $258 - $618	300 Added 297.03%	401 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $3.02 $142 - $235	-78 Reduced 43.58%	101 $0
Q4 2021 Feb 08, 2022	SELL	$2.88 - $4.3 $639 - $954	-222 Reduced 55.36%	179 $0
Q3 2021 Nov 15, 2021	SELL	$3.72 - $5.35 $66 - $96	-18 Reduced 4.3%	401 $2,000
Q2 2021 Sep 13, 2021	BUY	$3.83 - $5.98 $1,604 - $2,505	419 New	419 $2,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.